BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15759033)

  • 1. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen.
    Kennedy GA; Durrant S; Butler J; Morton J; Western R; Bartlett ML; Allison R; MacFarlane DJ
    Leukemia; 2005 May; 19(5):879-80. PubMed ID: 15759033
    [No Abstract]   [Full Text] [Related]  

  • 2. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
    Knop S; Dohmen BM; Kanz L; Bares R; Einsele H
    Haematologica; 2004 Sep; 89(9):ECR36. PubMed ID: 15377488
    [No Abstract]   [Full Text] [Related]  

  • 3. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
    Rodriguez V; Anderson PM; Litzow MR; Erlandson L; Trotz BA; Arndt CA; Khan SP; Wiseman GA
    Leuk Lymphoma; 2006 Aug; 47(8):1583-92. PubMed ID: 16966270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
    Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
    Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
    J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
    Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 153Sm: its use in multiple myeloma and report of a clinical experience.
    Abruzzese E; Iuliano F; Trawinska MM; Di Maio M
    Expert Opin Investig Drugs; 2008 Sep; 17(9):1379-87. PubMed ID: 18694370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [153Sm-EDTMP for moderate and severe bone cancer pain].
    Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Samarium-153-EDTMP dosimetry.
    Heggie JC
    J Nucl Med; 1994 Jan; 35(1):191-2. PubMed ID: 8271053
    [No Abstract]   [Full Text] [Related]  

  • 10. Samarium-153-EDTMP biodistribution and dosimetry estimation.
    Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
    J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor].
    Deng H; Tan T; Mo T; Zhong S; Kuan A; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Jun; 26(2):155-9. PubMed ID: 7490021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget's disease and rheumatoid arthritis.
    Alberts AS; Brighton SW; Kempff P; Louw WK; Beek AV; Kritzinger V; Westerink HP; van Rensburg AJ
    J Nucl Med; 1995 Aug; 36(8):1417-20. PubMed ID: 7543145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats].
    Shi B; Fu Z; Lei XH
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.
    Rodriguez V; Erlandson L; Arndt CA; Wiseman GA; Anderson PM
    Pediatr Transplant; 2005 Feb; 9(1):122-6. PubMed ID: 15667625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
    Weiss K; Köck HH; Atefie K; Sinzinger H
    Rev Esp Med Nucl; 2001 Jun; 20(4):311-2. PubMed ID: 11940421
    [No Abstract]   [Full Text] [Related]  

  • 19. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
    Clapp K
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
    Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.